—Dr. Munyikwa Appointed as Director of Regulatory Affairs—
—Dr. Renegar Appointed as Director, Company Analytics and Operations—
WOBURN, Mass., June 29, 2021 (World NEWSWIRE) — Generate10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience organization, these days announced two new hires. Tichafa Munyikwa, Ph.D. has been appointed Director of Regulatory Affairs. In this new purpose, Dr. Munyikwa will be liable for building and executing regulatory approach for Yield10’s performance and articles characteristics deployed in Camelina. In addition, Nicholas Renegar, Ph.D. has been appointed Director, Enterprise Analytics and Functions. In this new purpose, Dr. Renegar will be responsible for company analytics and challenge administration as well as supporting Generate10’s business enhancement, supply chain development, and seed functions pursuits.
“We are delighted to have Tichafa be a part of the Yield10 team as we are scaling up seed output and intensifying our attempts to develop and commercialize overall performance characteristics as properly as novel qualities to deliver nutritional oils, food and PHA bioplastics on our Camelina platform,” explained Oliver Peoples, Ph.D., President and Main Government Officer of Yield10. “Tichafa’s knowledge in significant agricultural organizations as effectively as with startups offers him with a unique standpoint on producing new crops and merchandise for the agricultural sector. We are confident he will make vital contributions and deliver our workforce with a must have strategic insights and direction on achieving regulatory approval to enable commercialization of our agbiotech crops and goods.”
“Nick brings to this function a strong background in meals safety and world-wide supply chain analytics, spots we will be focused on as we progress Produce10’s Camelina business enterprise approach,” stated Dr. Peoples. “We are delighted to welcome Nick to Produce10 and seem forward to his contributions as he will provide as an critical asset to the group as we expand our seed scale up throughout Canada, the U.S. and South The usa and as we intensify our professional and business enterprise improvement activities.”
Dr. Munyikwa possesses 25 years’ expertise functioning in the agriculture sector in a career spanning crop investigate and growth, world-wide regulatory affairs and administration as perfectly as properly acquiring regulatory approval for a number of genetically modified crops. From 2018 to 2021, he was Vice President, World-wide Regulatory Affairs for Trait Biosciences and Pebble Labs. From 2008 to 2018, Dr. Munyikwa held several positions at Syngenta Enterprise in regulatory affairs and trait R&D, most just lately as International Regulatory Affairs Guide for New Technologies and Early Stage Investigation Tasks (2014-2018) and Chair, Plant Breeding Innovations Staff, Genome Editing (2013 to 2018). From 1998 to 2007, Dr. Munyikwa was at Monsanto Organization (now Bayer) where he joined as a post-doc and became a Senior Analysis Scientist in the Biotechnology Plan in 1999. At Monsanto he was named an inventor on 6 issued patents and focused on experimental and commercialization methods for RNAi (gene silencing) technological know-how and mechanisms of plant condition resistance.
In his expert encounter, Dr. Munyikwa has been a board member for the International Enzyme Specialized Association, North Carolina Point out College Genetic Engineering & Society Institute, and the Association of African Agricultural Gurus in Diaspora (AAAPD). Dr. Munyikwa gained a Ph.D. at Wageningen University, The Netherlands. He gained an M.S. in Biotechnology – Molecular Biology, Fermentation Engineering and a B.S. in Organic Sciences Microbiology, Parasitology, Invertebrate Zoology from the University of Zimbabwe.
Dr. Renegar recently earned a Ph.D. in Functions Study from the MIT Sloan School of Administration, Cambridge, MA, the place he was suggested by Professor Retsef Levi. Even though pursuing his Ph.D., Dr. Renegar was a member of MIT’s Operations Research Heart, and MIT’s Food Provide Chain Analytics and Sensing (FSAS) Initiative. He has performed and printed analysis in food stuff protection, such as supply chain analytics, large knowledge and optimization, with a aim on global source chains and China. His Doctoral Thesis is entitled “Predictive Analytics and Machine Discovering for the Hazard-Primarily based Management of Agricultural Supply Chains”. Dr. Renegar has also worked on auction principle and on the internet algorithms, such as a investigation internship at Google, Inc. centered on system layout for lookup adverts. Prior to MIT, from 2010 to 2015, Dr. Renegar worked as a Health care Consulting Actuarial Analyst at Milliman, Inc. exactly where he used predictive analytics to assistance healthcare companies prepare for the future. Dr. Renegar gained a B.A. in Arithmetic and a B.S. in Operations Investigation at Cornell College.
About Generate10 Bioscience
Produce10 Bioscience, Inc. is an agricultural bioscience company that is employing its differentiated trait gene discovery system, the “Trait Factory”, to build improved Camelina varieties to produce proprietary seed goods, and to explore significant benefit genetic attributes for the agriculture and food items industries. Our goals are to efficiently create a large price seed products and solutions business enterprise based on establishing remarkable varieties of Camelina to deliver feedstock oils, dietary oils, and PHA bioplastics, and to license our generate qualities to key seed organizations for commercialization in important row crops, together with corn, soybean and canola. Yield10 is headquartered in Woburn, MA and has an Oilseeds Middle of Excellence in Saskatoon, Canada.
Protected Harbor for Forward-Wanting Statements
This press launch includes forward-seeking statements which are created pursuant to the harmless harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute guarantees of long run functionality. Traders are cautioned that statements in this press release which are not strictly historic, which include, without having limitation, that Dr. Munyikwa will make critical contributions and provide Generate10 with priceless strategic insights and steerage on attaining regulatory approval to enable commercialization of the Company’s agbiotech crops and goods, and that Dr. Renegar will serve as an significant asset to Generate10 as the Business expands its seed scale up throughout Canada, the U.S. and South America and as the Firm intensifies its professional and organization progress functions, constitute forward-searching statements. This sort of forward-on the lookout statements are topic to a range of threats and uncertainties that could result in actual final results to vary materially from those expected, such as the dangers and uncertainties specific in Produce10 Bioscience’s filings with the Securities and Exchange Fee. Generate10 assumes no obligation to update any forward-wanting information and facts contained in this press launch or with respect to the matters described herein.
Lynne H. Brum, (617) 682-4693, [email protected]
Bret Shapiro, (561) 479-8566, [email protected]
Controlling Director, Core IR
Eric Fischgrund, [email protected]